• search

Ranbaxy enters into exclusive licensing agreement with Swiss co

Written by: Staff

New Delhi, Oct 23 (UNI) Ranbaxy Laboratories Ltd today said it has signed an exclusive licensing agreement with Swiss biopharmaceutical development company, Debiopharm Group, to market the latter's New Chemical Entity (NCE) drug in India, Bangladesh and Nepal.

''We are glad to partner with Debiopharm in the gastroenterology area and shall work towards creating a productive relationship by complementing each others strengths. The agreement will enable Ranbaxy to increase its focus in this segment,'' Ranbaxy Regional Director (India and West Asia) Sanjeev Dani said.

Sanvar (vapreotide acetate), catering to the gastroenterology segment, is a synthetic octapeptide analogue of the naturally-occurring somatostatin hormone.

It has been granted orphan drug status in the US where it is presently undergoing Phase III clinical trials. Debiopharm expects to file Sanvar for approval in the US in the first quarter of 2007.

''These partnerships demonstrate the value that Sanvar can add to a growing portfolio of late-stage compounds and we look forward to developing these and future relationships, to maximise the potential of the product,'' said of Loic Maurel, President and CEO of the Canadian affiliate of Debiopharm.

Debiopharm Group is a global independent biopharmaceutical development company specialising in oncology and serious medical conditions.


For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more